Authors: G. Kaigala, J. VanDjinkin, B.J. Taylor, C.J. Backhouse and L.M. Pilarski
Affilation: University of Alberta, Canada
Pages: 49 - 52
Keywords: microfluidics, microchips, multiple myeloma, biomarkers, gene rearrangement
MM has a unique molecular signature and is well suited as a model system for performing analysis on microchips. MM multiplex genetic analysis for clonotypic signatures and genetic abnormalities offers the possibility for genetic profiling and monitoring. Analysis of ex-vivo cancer cells is performed in an automated, rapid, low-volume (nL) regime, leading to accelerated thermal kinetics by the use of a microfluidic platform. Both genomic DNA and IgH VDJ transcripts amplified from individual cells were detectable on-chip with 50pL of product, which accounts for 0.001% of the amplified product from one individual MM cell or from groups of MM cells. PCR on a chip with cDNA template from one single MM cell amplified the t(4;14) signature. Microfluidic platforms developed here employ novel technology for large scale genetic screening of MM patients, enabling predictions of risk and stratification for treatment, based on the genetic signature of each cancer.
Nanotech Conference Proceedings are now published in the TechConnect Briefs